Atorvastatin (CAS 134523-00-5) is a high-purity HMG-CoA reductase inhibitor API, a potent statin drug designed for the treatment of hypercholesterolemia and cardiovascular disease. With a precise molecular structure, it acts by selectively and competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. This inhibition leads to a significant reduction in serum total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglyceride levels, while increasing high-density lipoprotein cholesterol (HDL-C).
Produced under strict GMP standards, this API ensures consistent purity (≥99%) and stability, making it ideal for pharmaceutical formulation. It is widely applied in the development of drugs for the prevention and treatment of cardiovascular diseases, such as coronary artery disease, myocardial infarction, and stroke, catering to the needs of pharmaceutical manufacturers and research institutions in the field of cardiology and lipid metabolism.
Its unique ability to lower LDL-C levels and reduce cardiovascular events has made it a cornerstone drug in the management of dyslipidemia. Atorvastatin delivers reliable therapeutic benefits with a favorable safety profile, supporting the development of effective treatments for cardiovascular disorders.
